Sign in
CompletedNo phase

Prefrontal Oscillations in Social Anxiety Disorder (POSAD)

Key facts

Who runs it
Institut National de la Santé Et de la Recherche Médicale, France
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
20 people enrolled
Started
12 Nov 2019
Ended
9 May 2026
Type of study
Interventional, 3 groups
Treatments tested
  • In vivo social exposure
  • Social exposure in a virtual reality setting
  • EEG recording
  • Psychometric evaluation
  • Visual Analogue Scale of anxiety
Record updated
7 July 2026

Who can take part

Age
20 years to 50 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Social anxiety disorder as defined in DSM-5
  • Full understanding of the protocol
  • Obtaining informed consent from study subjects before or at inclusion at the latest
  • Being registered in the french national health insurance service (Sécurité Sociale) (or equivalent)

Who cannot take part

  • initiation of a psychotropic treatment or change in the dose of ongoing psychotropic treatment within 3 days prior to each visit and including:; antidepressant treatments with selective serotonin recapture inhibitors, serotonin and norepinephrine inhibitors, alpha2-presynaptic adrenoreceptors (mirtazapine, mianserin), tricyclic; anxiolytic drugs including benzodiazepines and anti-histamine; antipsychotic drugs
  • Acute alcohol intake 2 days prior to each visit (inclusion, experimental sessions)
  • Active medical co-morbidity including severe hypertension, cardiac insufficiency, Raynaud syndrome, diabetes mellitus, renal insufficiency, adrenal insufficiency, Cushing syndrome and epilepsy
  • Severe neurological co-morbidity, including but not limited to Parkinson's disease and multiple sclerosis
  • History of significant head injury, defined by loss of consciousness
  • Being diagnosed with another major psychiatric condition (DSM5) including bipolar disorder and schizophrenia or substance/alcohol use disorder; with the exception of major depressive disorder and nicotine use disorder
  • Long-term corticotherapy
  • Suicidal risk evaluated as moderate to high in the MINI questionnaire
  • Pregnancy or breastfeeding
  • Ongoing hospitalization without consent (decision of a third-party: medical, justice)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Experimental fear in rodents is correlated with slow oscillations in electrical recordings of prefrontal cortex activities. The present study aims to test whether slow prefrontal oscillations is a biomarker of pathological anxiety in human subjects.

The 3 groups in the trial

  • Group 1: Go-no-go phaseTreatment being tested

    The presence of significant prefrontal oscillations in the EEG recording 2-6Hz band during in vivo social exposure (oral presentation to examiners) will be assessed in 10 subjects with social anxiety disorder. EEG will be recorded immediately before, during and after oral presentations to examiners. Psychometric evaluation will be performed prior to experimental sessions. Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods (wainting, presentation, recovery). Results of EEG recordings in the first 10 subjects will lead to continuation (presence of significant slow prefrontal oscillations during anxiety) or interruption (absence of signification oscillation) of the study.

    Treatment: In vivo social exposure, EEG recording, Psychometric evaluation, and Visual Analogue Scale of anxiety

  • Group 2.1Treatment being tested

    In group 2.1, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after: 1. "real exposure": oral presentation to a panel of examiners 2. "virtual reality" : oral presentation to virtual examiners Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session. Psychometric evaluation will be performed prior to experimental sessions.

    Treatment: In vivo social exposure, Social exposure in a virtual reality setting, EEG recording, Psychometric evaluation, and Visual Analogue Scale of anxiety

  • Group 2.2Treatment being tested

    In group 2.2, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after: 1. "virtual reality" : oral presentation to virtual examiners 2. "real exposure": oral presentation to a panel of examiners Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session. Psychometric evaluation will be performed prior to experimental sessions.

    Treatment: In vivo social exposure, Social exposure in a virtual reality setting, EEG recording, Psychometric evaluation, and Visual Analogue Scale of anxiety

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Study of Slow Prefrontal Cortex Oscillations During Social Exposure in Social Anxiety Disorder
Record updated
7 July 2026